Malignant Melanoma
Conditions
Keywords
AdCD40L, Adenoviral vector, CD40L, CD154, malignant melanoma
Brief summary
In this phase I/II trial, immunostimulatory gene therapy (AdCD40L) will be investigated. In Part 1 patients with melanoma will receive AdCD40L as mono therapy. In Part 2A, patients with melanoma and patients with other solid tumors will receive AdCD40L in combination with low dose cyclophosphamide. In Part 2B, patients with melanoma will receive AdCD40L in combination with one local radiotherapy and cyclophosphamide.
Detailed description
In this phase I/II trial, immunostimulatory gene therapy (AdCD40L) will be investigated. In Part 1 patients with melanoma (n=6) will receive AdCD40L as mono therapy. In Part 2A, patients with melanoma (n=9) and patients with other solid tumors (n=6) will receive AdCD40L in combination with low dose cyclophosphamide. In Part 2B, patients with melanoma will receive AdCD40L in combination with one local radiotherapy and cyclophosphamide. AdCD40L is given by weekly injections of 2.5x10e11 VP, 4x; total dose 1x10e12 VP. A maximum of 30 patients will be included in this trial. AdCD40L is an adenoviral nonreplicating vector carrying the human CD40L gene. AdCD40L infects tumor cells upon intratumoral injection and deliver the CD40L gene into the cells whereupon the virus is destroyed. CD40L is then expressed as a membrane-bound protein and interacts with the CD40 receptor expressed by for example dendritic cells (DCs) in the tumor area. DCs mature upon CD40/CD40L interactions and activates tumor-specific T cell responses.
Interventions
BIOLOGICALAdCD40L
Adenoviral serotype 5 vector, E1/E3 deleted. Human CD40L gene insert driven by RSV promoter. Vector diluted in infusion solution, 500uL solution containing 2.5x10e11 VP is intratumorally injected/treatment.
Sponsors
Uppsala University Hospital
Uppsala University
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Histologically proven diagnosis of malignant solid cancer, ECOG 0-2. * Disease progression on established treatments or patients not eligible to standard options. * Signed informed consent must be obtained.
Exclusion criteria
* Pregnancy. * Life expectancy less than 3 months. * Any significant medical or psychiatric illness that would prevent the patient from giving informed consent or from following the study procedures. * Patients with severe systemic autoimmune disease. * Patients that do not consent to that tissue and blood samples are stored in a biobank.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| All cause adverse events | during 10 weeks | Adverse events will be documented such as inflammation, fever, pain, changes in blood pressure, pulse etc. |
| Immune reactions to adenovirus and spreading of vector | during 10 weeks | Immune reactions to adenovirus will be measured by evaluating the increase of anti-adenoviral antibodies in the patients at different time points using an ELISA. Spreading of vector will be evaluated by real time PCR to detect adenovirus vector copies in blood (plasma and erythrocyte fraction). |
Secondary
| Measure | Time frame |
|---|---|
| Tumor burden as measured by PET/CT and whole body MR | At enrollment, week 5 and week 9 |
Countries
Sweden
Outcome results
None listed